Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Amgen    AMGN

AMGEN (AMGN)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles

Amgen, Inc. : Amgen : FDA Letter Rejects Expanded Use Of Xgeva For Prostate Cancer

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 01:22pm CEST

Amgen Inc. (AMGN) received a complete response letter from the U.S. Food and Drug Administration rejecting the expanded use of Xgeva in men with prostate cancer that hasn't spread to the bones.

According to the drug maker, the FDA letter said the agency can't approve the supplemental biologics license application in its present form because the effect on bone metastases-free survival doesn't outweigh the risks, such as osteonecrosis of the jaw, a rare jaw-decay problem.

"We are reviewing the complete response letter and will work with FDA to determine any next steps," said Sean E. Harper, executive vice president of research and development.

Xgeva is currently approved to delay fractures and other bone injuries in patients whose cancer has already spread to the bones. It is also sold under the brand name Prolia as an osteoporosis treatment, but is administered at a lower dose. Xgeva's and Prolia's combined sales in 2011 topped $550 million.

A federal advisory panel in February rejected Amgen's proposal to expand the bone drug's use, saying it was unclear whether the results were clinically meaningful.

Amgen's study of Xgeva in men with prostate cancer that hadn't responded to previous therapies, but hadn't yet spread to the bones showed the drug prolonged median bone metastatis-free survival by 4.2 months.

Shares closed Thursday at $70.79 and were inactive premarket. The stock it up 10% so far this year.

-By Melodie Warner, Dow Jones Newswires; 212-416-2283; [email protected]

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AMGEN
06/23AMGEN : New Data Show Amgen's Repatha® (evolocumab) Significantly Reduced LDL-C ..
PU
06/21AMGEN : FDA Approves Addition Of Positive Overall Survival Data From Phase 3 ASP..
AQ
06/21Four companies in IPO quintet post first-day gains
AQ
06/21Five biopharmas price IPOs ahead of Thursday trading
AQ
06/19AMGEN : Receives European Commission Approval To Add Overall Survival Data To BL..
PR
06/15AMGEN : FDA Approves Addition of Positive Overall Survival Data from Phase 3 ASP..
AQ
06/14AMGEN : Patent Issued for Salt of Omecamtiv Mecarbil and Process for Preparing S..
AQ
06/14AMGEN : European Commission Approves Prolia® denosumab for Patients With Glucoco..
AQ
06/14AMGEN : Patent Issued for Injector and Method of Assembly (USPTO 9987428)
AQ
06/14AMGEN : Reports Summarize Clinical Trials and Studies Findings from Amgen (A Ran..
AQ
More news
News from SeekingAlpha
06/23What Does Breakthrough Therapy Designation Really Mean For My Company? 
06/22Roche sues Amgen over Herceptin biosimilar 
06/22Arrowhead Pharmaceuticals - Pullbacks Are Becoming Rare, So Take Advantage If.. 
06/223 Calls 3 Different Reasons 
06/21Neon Therapeutics Firms Its Plan For $100 Million IPO 
Financials ($)
Sales 2018 22 701 M
EBIT 2018 11 643 M
Net income 2018 8 740 M
Finance 2018 10 236 M
Yield 2018 2,80%
P/E ratio 2018 14,83
P/E ratio 2019 14,06
EV / Sales 2018 4,95x
EV / Sales 2019 4,90x
Capitalization 123 B
Chart AMGEN
Duration : Period :
Amgen Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Technical analysis trends AMGEN
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Average target price 195 $
Spread / Average Target 5,5%
EPS Revisions
Managers
NameTitle
Robert A. Bradway Chairman & Chief Executive Officer
Esteban Santos Executive Vice President-Operations
David W. Meline CFO, Chief Accounting Officer & Executive VP
Frank C. Herringer Independent Director
Rebecca M. Henderson Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
AMGEN6.47%122 515
JOHNSON & JOHNSON-12.27%329 475
PFIZER0.22%213 568
NOVARTIS-9.42%191 991
ROCHE HOLDING LTD.-12.58%191 785
MERCK AND COMPANY8.90%165 373